Overweight and Obesity — Capturing the Whole Picture

This editorial discusses the global rise in overweight and obesity, focusing on China, where the prevalence has surged dramatically. It highlights a phase 3 trial of mazdutide, a dual GLP1 and glucagon receptor agonist, in Chinese adults with overweight or obesity. The trial demonstrated significant weight loss and improvements in metabolic markers, emphasizing the need for comprehensive risk assessment and early intervention. The editorial also underscores the importance of tailored treatments for different populations and the broader public health strategies required to address obesity globally.

This editorial discusses the global rise in overweight and obesity, focusing on China, where the prevalence has surged dramatically. It highlights a phase 3 trial of mazdutide, a dual GLP1 and glucagon receptor agonist, in Chinese adults with overweight or obesity. The trial demonstrated significant weight loss and improvements in metabolic markers, emphasizing the need for comprehensive risk assessment and early intervention. The editorial also underscores the importance of tailored treatments for different populations and the broader public health strategies required to address obesity globally.